IQUIMEFA   05518
INSTITUTO QUIMICA Y METABOLISMO DEL FARMACO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Detection of a tadalafil analogue as an adulterant in a dietary supplement for erectile dysfunction
Autor/es:
ULLOA JERÓNIMO; SAMBROTTA LUIS; REDKO FLAVIA; MAZZA OSVALDO; GARRIDO GUSTAVO; BECHER EDGARDO; MUSCHIETTI LILIANA
Lugar:
Sao Paulo
Reunión:
Encuentro; 16th World Meeting on Sexual Medicine; 2014
Institución organizadora:
International Society on Sexual Medicine -
Resumen:
Introduction
Erectile dysfunction (ED) is a common and
widespread health problem whose worldwide
prevalence in 2025 is estimated to rise to 322
million cases per year.
cGMP-specific phosphodiesterase type 5 enzyme
inhibitors (PDE-5i) such as tadalafil, sildenafil and
vardenafil are massively used around the world
with a good safety profile. However, these drugs
are contraindicated in men taking nitrates and need
to be administered carefully in subjects under
multiple antihypertensive medications.
Several cases of adulteration of dietary
supplements with PDE-5i or their unapproved
analogues have been reported worldwide. Mainly,
the presence of the latter represents a serious
health risk to consumers as their efficacy and toxic
effects have not been assessed and may result in
unpredictable adverse effects.